3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Gastrointestinal
5
Genitourinary
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
95
Head and Neck Neoplasms
92
Nasopharyngeal Carcinoma
35
Nasopharyngeal Neoplasms
15
Laryngeal Neoplasms
12
Oropharyngeal Neoplasms
10
Mouth Neoplasms
10
Hypopharyngeal Neoplasms
9
Colorectal Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
7
Carcinoma, Squamous Cell
7
Neoplasm Metastasis
6
Esophageal Neoplasms
6
Carcinoma
6
Stomach Neoplasms
5
Tongue Neoplasms
4
Recurrence
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Ovarian Neoplasms
4
Laryngeal Diseases
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Sarcoma
3
Salivary Gland Neoplasms
3
Lung Neoplasms
3
Breast Neoplasms
3
Thyroid Neoplasms
2
Pharyngeal Neoplasms
2
Interventions
pembrolizumab
19
Paclitaxel
6
Trastuzumab
5
Nivolumab
5
palbociclib
4
Carboplatin
4
Biopsy
4
lenvatinib
3
Taxes
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Immunoglobulin G
3
Fulvestrant
3
Cyclophosphamide
3
Cetuximab
3
trastuzumab deruxtecan
2
tisotumab vedotin
2
spartalizumab
2
sargramostim
2
gedatolisib
2
fludarabine
2
epacadostat
2
capivasertib
2
X-Rays
2
Sunitinib
2
Docetaxel
2
Disulfides
2
Cisplatin
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Fluorouracil
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled